Clinical Trial

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Study acronym: DFMO
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the feasibility of administering DL-alpha-difluoromethylornithine (DFMO) to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-19; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2025-05-06
Trial Details
NCT Number NCT06892678
Lead Sponsor Montefiore Medical Center
Collaborators: Johns Hopkins University
Conditions Osteosarcoma Recurrent, Ewing's Tumor Recurrent
Enrollment 15 participants
Start Date 2025-04-07
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-14